Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | F2 | P00734 | 4/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5649641 | 0.84 | F2 (0.58) | KDM4EMEN1KMT2AF2ALDH1A1 | |
| SCHEMBL5652515 | 0.76 | F2 (0.59) | KDM4EMEN1KMT2AF2ALDH1A1 | |
| SCHEMBL5647154 | 0.75 | F2 (0.49) | MEN1KMT2AF2ALDH1A1SMN1; SMN2 | |
| SCHEMBL30632615 | 0.74 | HTT (0.60) | MEN1KMT2ATDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL4338 | 0.74 | HTT (0.60) | MEN1KMT2ATDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL5649003 | 0.73 | F2 (0.41) | KDM4EMEN1KMT2AF2ALDH1A1 | |
| SCHEMBL30645136 | 0.71 | FFAR4 (0.54) | KDM4EMEN1KMT2ATDP1ALDH1A1 | |
| Nitrogen SCHEMBL29173898 | 0.71 | HTT (0.57) | MEN1KMT2ATDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL365306 | 0.71 | FFAR4 (0.54) | KDM4EMEN1KMT2ATDP1ALDH1A1 | |
| SCHEMBL5651411 | 0.70 | F2 (0.61) | F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161643-A1 | Pyridin-2-one compounds useful as inhibitors of thrombin | ASTRAZENECA AB (SE) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161643-A1 | Pyridin-2-one compounds useful as inhibitors of thrombin | PLG, F2, PLAT | KDM4E 2691/4885MEN1 1252/4885KMT2A 2105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.